Chimerically designed HDAC- and tyrosine kinase inhibitors. A series of erlotinib hybrids as dual-selective inhibitors of EGFR, HER2 and histone deacetylases

Thomas Beckers, Siavosh Mahboobi, Andreas Sellmer, Matthias Winkler, Emerich Eichhorn, Herwig Pongratz, Thomas Maier, Thomas Ciossek, Thomas Baer, Gerhard Kelter, Heinz-Herbert Fiebig, Mathias Schmidt
  • MedChemComm, January 2012, Royal Society of Chemistry
  • DOI: 10.1039/c2md00317a
The author haven't yet claimed this publicationThe author haven't yet claimed this publication

In partnership with: